Organization Profile

UCB

You just read:

Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study

News provided by

UCB

Mar 02, 2019, 07:00 ET